Clinical Trials Sponsored by CBI Health

Total 50689 results

University of Waterloo
CBI Health

Completed

Efficacy of a Remotely Administered Functional Capacity Test on Return-to-work Outcomes

Musculoskeletal Injury | Shoulder Disease | Low Back Disorder

Canada
Dave Walton
CBI Health

Recruiting

Multi-axis Assessment of Injured Workers

Low Back Pain | Neck Pain | Upper Extremity Injury | Lower Extremity Problem | Musculoskeletal Injury | Work-related Injury | Musculoskeletal Strain

Canada
Texas Heart Institute
CHI St. Luke's Health, Texas

Completed

Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)

Ischemic Cardiomyopathy

United States
Texas Heart Institute
Aldagen; CHI St. Luke's Health, Texas

Completed

Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)

Coronary Artery Disease

United States
CHI St. Luke's Health, Texas
Medtronic - MITG

Completed

Multicenter Myocardial Viability Trial

Coronary Artery Disease

United States, Thailand, Belgium, Denmark, Greece, United Kingdom
Creighton University
CHI Nebraska Heart

Completed

The Impact of a Heart Failure Review on Self-Care Knowledge, Adherence and Clinical Outcomes

Heart Failure

United States
CTI BioPharma

Completed

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
CTI BioPharma

Terminated

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. (PIONEER)

NSCLC

United States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
CTI BioPharma

Terminated

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

Canada, United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
CVI Pharmaceuticals

Unknown

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

Hyperlipidemia

China
Galilee CBR

Unknown

Personalized Nutrition Prediction for Metabolic Syndrome Patients, an Open Single-center Study

Metabolic Syndrome
CTI BioPharma

Completed

A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin (RAPID)

Diffuse Large-Cell Lymphoma

United States, Germany, Canada, Italy, France
CTI BioPharma

Completed

Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer

Colorectal Cancer

Italy
CTI BioPharma

Withdrawn

Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment (Hepatic)

Metastatic Cancer

United States
CTI BioPharma

Completed

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post- Essential Thrombocythemia Myelofibrosis

United States, Spain, United Kingdom, Hungary, Korea, Republic of, France, Italy, Sweden
CTI BioPharma

Withdrawn

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma | Leukemia

United States
CTI BioPharma

Terminated

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Completed

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States, United Kingdom, France, Italy, India, Germany, Hungary, Argentina, Uruguay, Russian Federation, Bulgaria, Costa Rica, Ecuador, Estonia, Mexico, Panama, Peru, Poland, Romania, Ukraine
CTI BioPharma

Withdrawn

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Lymphoma | Solid Tumor (Excluding CNS)

United States
Galilee CBR

Unknown

Study of Absorption Characteristics of Two Multivitamin Mineral Formulations (Gel vs. Tablet/Capsule)

Vitamin Deficiency
CTI BioPharma

Completed

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade | Lymphoma, Small Lymphocytic

United States
CBA Research

Terminated

A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
CTI BioPharma

Completed

CT-2106 for the Second Line Treatment of Ovarian Cancer

Ovarian Cancer

France, United Kingdom, Italy
CTI BioPharma

Terminated

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

COVID-19 | COVID | COVID19

United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (PAC326)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
CTI BioPharma

Terminated

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

Prostate Cancer

United States
CTI BioPharma

Withdrawn

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

NSCLC

United States
CTI BioPharma

Withdrawn

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Non-Hodgkin's Lymphoma

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
CBA Research

Unknown

CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin

Sarcoma

United States
CTI BioPharma

Terminated

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Follicular | Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade

United States
CLI Foundation

Unknown

Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction (COCTAIL II)

ST-elevation Myocardial Infarction

Italy
CTI BioPharma

Completed

Phase II CT-2103/Carboplatin in Ovarian Cancer

Ovarian Neoplasm

United States
Tzu Chi University

Recruiting

Chatbot Facilitated Education on Child and Adolescent Abuse

Child Abuse

Taiwan
VBI Vaccines Inc.

Recruiting

PREHEVBRIO Pregnancy Outcomes Registry

Vaccine Exposure During Pregnancy

United States
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan
OBI Pharma, Inc

Terminated

A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors

Pancreatic Adenocarcinoma | Solid Tumor

United States
UBI Pharma Inc.

Completed

Study to Compare the Safety and Efficacy of UB-851 and Eprex®

Renal Anemia
CTI BioPharma
Covance

Completed

To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

Healthy Subjects

United States
CTI BioPharma
Covance

Completed

Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects

Healthy Subjects

United States
VBI Vaccines Inc.

Active, not recruiting

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a

Coronavirus Infections | COVID-19

Canada
VBI Vaccines Inc.

Completed

Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

Hepatitis B

Russian Federation
Tzu Chi University

Unknown

The Effects of Baduanjin Exercise on Meridian Energy and Heart Rate Variability in Patients Undergoing Cardiac Sugery

Open Heart Surgery

Taiwan
VBI Vaccines Inc.

Completed

Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults

Hepatitis B Vaccines

United States, Canada, Finland, Belgium
CTI BioPharma
Covance

Completed

To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

Drug Interaction Study

United States
Tzu Chi University

Unknown

Development and Evaluation of E-training and Mentoring Support Program on Dementia Care for Home-care Workers

Dementia

Taiwan

3

Subscribe